IM Cannabis (IMCC) Competitors $1.97 +0.02 (+1.03%) Closing price 03:59 PM EasternExtended Trading$1.98 +0.02 (+0.76%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. LVTX, XLO, RNXT, NEUP, JSPR, OKUR, VRCA, DYAI, ELUT, and LIMNShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include LAVA Therapeutics (LVTX), Xilio Therapeutics (XLO), RenovoRx (RNXT), Neuphoria Therapeutics (NEUP), Jasper Therapeutics (JSPR), OnKure Therapeutics (OKUR), Verrica Pharmaceuticals (VRCA), Dyadic International (DYAI), Elutia (ELUT), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Its Competitors LAVA Therapeutics Xilio Therapeutics RenovoRx Neuphoria Therapeutics Jasper Therapeutics OnKure Therapeutics Verrica Pharmaceuticals Dyadic International Elutia Liminatus Pharma IM Cannabis (NASDAQ:IMCC) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Is IMCC or LVTX more profitable? LAVA Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -4.19%. IM Cannabis' return on equity of -59.80% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-4.19% -59.80% -5.15% LAVA Therapeutics N/A -106.29%-38.24% Do analysts prefer IMCC or LVTX? LAVA Therapeutics has a consensus target price of $2.69, suggesting a potential upside of 77.23%. Given LAVA Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe LAVA Therapeutics is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IM Cannabis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00LAVA Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Which has preferable valuation & earnings, IMCC or LVTX? IM Cannabis has higher revenue and earnings than LAVA Therapeutics. IM Cannabis is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$39.44M0.26-$7.72M-$0.54-3.65LAVA Therapeutics$11.98M3.33-$25.11M-$1.05-1.44 Do institutionals and insiders believe in IMCC or LVTX? 7.7% of IM Cannabis shares are held by institutional investors. 5.9% of IM Cannabis shares are held by insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, IMCC or LVTX? IM Cannabis has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Does the media refer more to IMCC or LVTX? In the previous week, LAVA Therapeutics had 8 more articles in the media than IM Cannabis. MarketBeat recorded 10 mentions for LAVA Therapeutics and 2 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 0.95 beat LAVA Therapeutics' score of 0.11 indicating that IM Cannabis is being referred to more favorably in the media. Company Overall Sentiment IM Cannabis Positive LAVA Therapeutics Neutral SummaryIM Cannabis beats LAVA Therapeutics on 8 of the 15 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.23M$10.68B$6.11B$10.47BDividend YieldN/A1.91%5.73%4.77%P/E Ratio-3.6520.5185.3627.36Price / Sales0.2626.68607.44135.43Price / CashN/A25.0737.4661.86Price / Book1.913.4812.426.81Net Income-$7.72M$208.83M$3.32B$276.80M7 Day Performance-1.50%-0.29%1.01%0.27%1 Month Performance2.07%3.71%10.75%8.31%1 Year Performance-8.04%-4.01%76.20%35.60% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.6499 of 5 stars$1.97+1.0%N/A-14.5%$10.23M$39.44M-3.65340Gap UpLVTXLAVA Therapeutics1.8654 of 5 stars$1.53-0.6%$2.69+75.5%-3.8%$40.51M$11.98M-1.4660Insider TradeXLOXilio Therapeutics1.9955 of 5 stars$0.76-2.2%$3.00+295.3%-2.2%$40.22M$6.34M-1.0070RNXTRenovoRx2.1885 of 5 stars$1.09+0.9%$7.50+588.1%+9.0%$39.58M$40K-2.876NEUPNeuphoria Therapeutics2.2003 of 5 stars$16.05-4.0%$28.00+74.5%N/A$39.42M$15.65M0.00N/AJSPRJasper Therapeutics3.4165 of 5 stars$2.51+4.6%$25.63+920.9%-84.9%$39.01MN/A-0.4220OKUROnKure Therapeutics3.742 of 5 stars$2.89+0.3%$32.33+1,018.8%-84.5%$38.97MN/A0.00N/AVRCAVerrica Pharmaceuticals3.9302 of 5 stars$4.11+0.2%$60.00+1,359.9%-71.1%$38.73M$7.57M-0.5040News CoverageDYAIDyadic International3.2458 of 5 stars$1.05-1.9%$6.00+471.4%+0.0%$38.72M$3.49M-5.537ELUTElutia3.1583 of 5 stars$0.89-2.0%$7.00+689.1%-76.3%$38.36M$24.38M-0.84180News CoverageLIMNLiminatus PharmaN/A$1.35-4.3%N/AN/A$38.16MN/A0.00N/APositive News Related Companies and Tools Related Companies LVTX Competitors XLO Competitors RNXT Competitors NEUP Competitors JSPR Competitors OKUR Competitors VRCA Competitors DYAI Competitors ELUT Competitors LIMN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
